CERENOVUS Unveils Clinical Data and Showcases New Product Innovations to Change the Trajectory of Stroke at the Society of NeuroInterventional Surgery 19th Annual Meeting

Cerenovus Logo

On-site experience will include scientific poster sessions with new clinical data and interactive product demonstrations

IRVINE, CA – July 20, 2022 – CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson MedTech,* will showcase its latest innovations in stroke care at the Society of NeuroInterventional Surgery (SNIS) 2022 Annual Meeting taking place in Toronto, Ontario, Canada from July 25-29. CERENOVUS will announce new clinical data during poster sessions and feature new innovations across its ischemic and hemorrhagic portfolios that reflect the company’s continued commitment to changing the trajectory of stroke.

“When it comes to stroke, we recognize the continuing opportunity to address unmet clinical needs, which ultimately can provide better outcomes for both patients and physicians,” said Mark Dickinson, Worldwide President, CERENOVUS. “We’re looking forward to sharing our latest research and newest additions to our ischemic and hemorrhagic portfolios that build on our commitment to changing the trajectory of stroke.”

Key Poster Presentations
CERENOVUS is supporting two scientific poster sessions at SNIS 2022, including one oral presentation and one ePoster:

  • Oral poster: “Interim safety and occlusion outcomes of endovascular treatment of ‘very small intracranial aneurysms’ in the STERLING registry” 
    • Date & Time: Monday, July 25, from 4:15 – 5:45pm ET
  • EPoster Title: “PulseRider-assisted treatment of intracranial aneurysms in the STERLING registry” 

Interactive Experiences in Booth 201
CERENOVUS will host a variety of interactive experiences at its booth, including hands-on demonstrations featuring technologies from its ischemic and hemorrhagic portfolios. The highlight for ischemic will be CERENVOUS Stroke Solutions™, a suite of solutions based on science and integration for better performance. The main focus will be on the latest addition to the Stroke Solutions family - EMBOGUARD™, a next generation balloon guide catheter used in endovascular procedures including acute ischemic stroke. On display from the hemorrhagic portfolio will be the CEREPAK™ Family of Coils, featuring a state-of-the-art delivery system designed with ease of use in mind to embolize brain aneurysms. 

During the lunch breaks on Tuesday, July 26th and Wednesday, July 27th, CERENOVUS is proud to sponsor physician-led in-booth demonstrations. These will be mobile, TED Talk-like experiences where attendees can join and interact to learn more about specific products, including the use of CERENOVUS EMBOGUARD™ and Stroke Solutions for ischemic stroke, as well as the use of EMBOGUARD™ in carotid stenting. These sessions will be led by Mahmood Mirza, MD and Jan-Karl Burkhardt, MD. 

In addition, CERENOVUS will debut an institution-oriented racial disparity in stroke care (RDiSC) metric picklist tool at the booth. The RDiSC tool can be used to assess and benchmark a hospital’s stroke outcomes across their patient population by race. The insight derived may be used to uncover focus areas of improvement in closing the racial disparity gap that exist along the stroke care pathway. 

Sponsored Programs and Receptions On-Site
CERENOVUS is proud to sponsor multiple programs and receptions on-site during the meeting, building on their commitment to diversity, equity and inclusion, as well as supporting women in neurointervention and continuing education for Fellows. These receptions include:

  • Women in Neurointervention Leadership Program – This all-day program will be held on Sunday, July 24th, where participants can reflect on their career goals and challenges, share their knowledge and experience with their peers, and build their leadership skills. The program will be hosted by leading authorities on women in leadership, Leanne Meyer and Sara Laschever.
  • Diversity, Equity & Inclusion Reception – This reception will be held on Monday, July 25th from 5:45 – 6:45pm ET and focus on the latest topics in DE&I.
  • Annual Women in NeuroIntervention Dinner – This dinner will be held on Wednesday, July 27th from 6:30 – 9:00pm ET and will focus on the state of female leaders, highlighting actionable steps to take to overcome current challenges.
  • Fellows Course Hands-On Lab & Reception – This event is taking place on Thursday, July 28th at 5:30pm ET and will consist of hands-on demonstrations of solutions.

For more information about CERENOVUS at #SNIS22, connect with us on Twitter and LinkedIn.

Media Contact: 
Samantha Yakal-Kremski
[email protected]

CERENOVUS, part of Johnson & Johnson MedTech, is an emerging leader in neurovascular care. Our commitment to changing the trajectory of stroke is inspired by our long heritage and dedication to helping physicians protect people from a lifetime of hardship. CERENOVUS offers a broad portfolio of devices used in the endovascular treatment of hemorrhagic and ischemic stroke. For more information, visit www.cerenovus.com and connect on LinkedIn and Twitter.

About Johnson & Johnson MedTech
As the world’s most comprehensive medical devices business, we are building on a century of experience, merging science and technology, to shape the future of health and benefit even more people around the world. With our unparalleled breadth, depth and reach across surgery, orthopedics, vision and interventional solutions, we’re working to profoundly change the way care is delivered. We are in this for life. For more information, visit www.jnjmedicaldevices.com

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding CERENOVUS EMBOGUARD™ and CEREPAK™. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of CERENOVUS, any of the other Johnson & Johnson Medtech and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither CERENOVUS, any of the other Johnson & Johnson MedTech nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

*The Johnson & Johnson MedTech comprise the surgery, orthopaedics, vision and interventional solutions businesses. CERENOVUS is part of the Johnson & Johnson MedTech.